198 related articles for article (PubMed ID: 25003579)
1. Decitabine reactivated pathways in platinum resistant ovarian cancer.
Fang F; Zuo Q; Pilrose J; Wang Y; Shen C; Li M; Wulfridge P; Matei D; Nephew KP
Oncotarget; 2014 Jun; 5(11):3579-89. PubMed ID: 25003579
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic resensitization to platinum in ovarian cancer.
Matei D; Fang F; Shen C; Schilder J; Arnold A; Zeng Y; Berry WA; Huang T; Nephew KP
Cancer Res; 2012 May; 72(9):2197-205. PubMed ID: 22549947
[TBL] [Abstract][Full Text] [Related]
3. A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer.
Fang F; Balch C; Schilder J; Breen T; Zhang S; Shen C; Li L; Kulesavage C; Snyder AJ; Nephew KP; Matei DE
Cancer; 2010 Sep; 116(17):4043-53. PubMed ID: 20564122
[TBL] [Abstract][Full Text] [Related]
4. Carboplatin with Decitabine Therapy, in Recurrent Platinum Resistant Ovarian Cancer, Alters Circulating miRNAs Concentrations: A Pilot Study.
Benson EA; Skaar TC; Liu Y; Nephew KP; Matei D
PLoS One; 2015; 10(10):e0141279. PubMed ID: 26485143
[TBL] [Abstract][Full Text] [Related]
5. A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer.
Glasspool RM; Brown R; Gore ME; Rustin GJ; McNeish IA; Wilson RH; Pledge S; Paul J; Mackean M; Hall GD; Gabra H; Halford SE; Walker J; Appleton K; Ullah R; Kaye S;
Br J Cancer; 2014 Apr; 110(8):1923-9. PubMed ID: 24642620
[TBL] [Abstract][Full Text] [Related]
6. Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways.
Tomar T; de Jong S; Alkema NG; Hoekman RL; Meersma GJ; Klip HG; van der Zee AG; Wisman GB
Genome Med; 2016 Oct; 8(1):107. PubMed ID: 27765068
[TBL] [Abstract][Full Text] [Related]
7. Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo.
Steele N; Finn P; Brown R; Plumb JA
Br J Cancer; 2009 Mar; 100(5):758-63. PubMed ID: 19259094
[TBL] [Abstract][Full Text] [Related]
8. Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer.
Fu S; Hu W; Iyer R; Kavanagh JJ; Coleman RL; Levenback CF; Sood AK; Wolf JK; Gershenson DM; Markman M; Hennessy BT; Kurzrock R; Bast RC
Cancer; 2011 Apr; 117(8):1661-9. PubMed ID: 21472713
[TBL] [Abstract][Full Text] [Related]
9. Sequential azacitidine and carboplatin induces immune activation in platinum-resistant high-grade serous ovarian cancer cell lines and primes for checkpoint inhibitor immunotherapy.
Wong-Brown MW; van der Westhuizen A; Bowden NA
BMC Cancer; 2022 Jan; 22(1):100. PubMed ID: 35073851
[TBL] [Abstract][Full Text] [Related]
10. Promoter hypermethylation of FBXO32, a novel TGF-beta/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer.
Chou JL; Su HY; Chen LY; Liao YP; Hartman-Frey C; Lai YH; Yang HW; Deatherage DE; Kuo CT; Huang YW; Yan PS; Hsiao SH; Tai CK; Lin HJ; Davuluri RV; Chao TK; Nephew KP; Huang TH; Lai HC; Chan MW
Lab Invest; 2010 Mar; 90(3):414-25. PubMed ID: 20065949
[TBL] [Abstract][Full Text] [Related]
11. Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors.
Appleton K; Mackay HJ; Judson I; Plumb JA; McCormick C; Strathdee G; Lee C; Barrett S; Reade S; Jadayel D; Tang A; Bellenger K; Mackay L; Setanoians A; Schätzlein A; Twelves C; Kaye SB; Brown R
J Clin Oncol; 2007 Oct; 25(29):4603-9. PubMed ID: 17925555
[TBL] [Abstract][Full Text] [Related]
12. Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling.
Zeller C; Dai W; Steele NL; Siddiq A; Walley AJ; Wilhelm-Benartzi CS; Rizzo S; van der Zee A; Plumb JA; Brown R
Oncogene; 2012 Oct; 31(42):4567-76. PubMed ID: 22249249
[TBL] [Abstract][Full Text] [Related]
13. Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer.
Balch C; Yan P; Craft T; Young S; Skalnik DG; Huang TH; Nephew KP
Mol Cancer Ther; 2005 Oct; 4(10):1505-14. PubMed ID: 16227399
[TBL] [Abstract][Full Text] [Related]
14. Low Dose Decitabine Combined with Taxol and Platinum Chemotherapy to Treat Refractory/Recurrent Ovarian Cancer: An Open-Label, Single-Arm, Phase I/II Study.
Fu X; Zhang Y; Wang X; Chen M; Wang Y; Nie J; Meng Y; Han W
Curr Protein Pept Sci; 2015; 16(4):329-36. PubMed ID: 25929868
[TBL] [Abstract][Full Text] [Related]
15. Hydroxycarbamide in combination with azacitidine or decitabine is antagonistic on DNA methylation inhibition.
Choi SH; Byun HM; Kwan JM; Issa JP; Yang AS
Br J Haematol; 2007 Sep; 138(5):616-23. PubMed ID: 17686055
[TBL] [Abstract][Full Text] [Related]
16. Genome-wide methylation and expression profiling identifies promoter characteristics affecting demethylation-induced gene up-regulation in melanoma.
Rubinstein JC; Tran N; Ma S; Halaban R; Krauthammer M
BMC Med Genomics; 2010 Feb; 3():4. PubMed ID: 20144234
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer.
Aird RE; Cummings J; Ritchie AA; Muir M; Morris RE; Chen H; Sadler PJ; Jodrell DI
Br J Cancer; 2002 May; 86(10):1652-7. PubMed ID: 12085218
[TBL] [Abstract][Full Text] [Related]
18. Combination of azacytidine and curcumin is a potential alternative in decitabine-resistant colorectal cancer cells with attenuated deoxycytidine kinase.
Hosokawa M; Seiki R; Iwakawa S; Ogawara KI
Biochem Biophys Res Commun; 2021 Nov; 578():157-162. PubMed ID: 34571370
[TBL] [Abstract][Full Text] [Related]
19. Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy.
Chen MY; Liao WS; Lu Z; Bornmann WG; Hennessey V; Washington MN; Rosner GL; Yu Y; Ahmed AA; Bast RC
Cancer; 2011 Oct; 117(19):4424-38. PubMed ID: 21491416
[TBL] [Abstract][Full Text] [Related]
20. Genomic and Epigenomic Signatures in Ovarian Cancer Associated with Resensitization to Platinum Drugs.
Fang F; Cardenas H; Huang H; Jiang G; Perkins SM; Zhang C; Keer HN; Liu Y; Nephew KP; Matei D
Cancer Res; 2018 Feb; 78(3):631-644. PubMed ID: 29229600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]